-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TCQXbmcsHcHlePPluxMabwKr8Nnlh/IuUcqMpO9srJ7osmjjP251Wr/Klcx/mcaa dQpxGPsD3uU1bD3quUh9YQ== 0000950123-10-035760.txt : 20100419 0000950123-10-035760.hdr.sgml : 20100419 20100419070518 ACCESSION NUMBER: 0000950123-10-035760 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100419 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20100419 DATE AS OF CHANGE: 20100419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALKERMES INC CENTRAL INDEX KEY: 0000874663 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232472830 STATE OF INCORPORATION: PA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14131 FILM NUMBER: 10756079 BUSINESS ADDRESS: STREET 1: 852 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451-1420 BUSINESS PHONE: (781)609-6000 MAIL ADDRESS: STREET 1: 852 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451-1420 8-K 1 b80569e8vk.htm ALKERMES, INC. e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 19, 2010
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
         
PENNSYLVANIA   1-14131   23-2472830
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
     
852 Winter Street
Waltham, Massachusetts 		  02451-1420
(Address of principal executive offices)   (Zip Code)
     Registrant’s telephone number, including area code:  (781) 609-6000
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01.   Regulation FD Disclosure
On April 19, 2010, Eli Lilly and Co. (“Lilly”) and Amylin Pharmaceuticals, Inc (“Amylin”) announced that Lilly submitted the Marketing Authorization Application filing for BYDUREON™ (exenatide for extended-release injectable suspension) for the treatment of type 2 diabetes to the European Medicines Agency. Alkermes, Inc. (“Alkermes”), Amylin, and Lilly are working together to develop BYDUREON, a subcutaneous injection of exenatide for the treatment of type 2 diabetes that utilizes Alkermes’ proprietary Medisorb® technology to create an extended-release injection. BYDUREON is not currently approved by any regulatory agencies. This information shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ALKERMES, INC.
 		  
Date: April 19, 2010  By:   /s/ James M. Frates    
    James M. Frates   
    Senior Vice President, Chief Financial Officer and Treasurer   
 

3

-----END PRIVACY-ENHANCED MESSAGE-----